According to a survey investigating 3,050 EGFR+ NSCLC samples, the emergence of TPM3-NTRK1 was confirmed to follow the initiation of EGFR-TKI erlotinib treatment through the comparison between paired pre- and after-treatment samples (111). This evidence concerns the gene EGFR and non-small cell lung carcinoma.